Drugs that boost a brain glutamate transporter to reduce alcohol dependence
Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies
Testing new compounds that increase a brain protein that clears glutamate to help people with alcohol dependence drink less and avoid relapse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-11098521 on NIH RePORTER |
What this research studies
From a patient perspective: researchers are developing novel compounds that raise levels of GLT-1, a brain protein that helps clear excess glutamate linked to alcohol craving and relapse. They will test these compounds and a non-antibiotic β-lactam in lab models to measure drinking-related behaviors, brain target engagement, drug levels, and inflammatory markers. The team will use pharmacokinetic and pharmacodynamic studies and look for biomarkers that indicate the drug is hitting its target and changing brain chemistry. Findings will be used to pick dosing and biomarkers for future human clinical trials if results look promising.
Who could benefit from this research
Good fit: Adults with alcohol dependence or heavy, uncontrolled alcohol use who are seeking new treatment options would be the likely candidates for future clinical trials based on this work.
Not a fit: People without alcohol dependence or whose drinking is driven primarily by non-glutamate mechanisms or social factors may not benefit from this approach.
Why it matters
Potential benefit: If successful, this work could lead to new medications that reduce craving, heavy drinking, and relapse in people with alcohol dependence.
How similar studies have performed: Preclinical studies with β-lactam antibiotics such as ceftriaxone have reduced alcohol intake and relapse in alcohol-preferring rats, but clinical testing in people is limited and these new compounds aim to avoid antibiotic effects.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Sari, Youssef — University of Toledo Health Sci Campus
- Study coordinator: Sari, Youssef
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.